Comparison of PAM50 risk of recurrence (ROR) score with oncotypeDx and IHC4 for predicting residual risk of RFS and distant-(D)RFS after endocrine therapy: a TransATAC study (Abstract S4-5; Dowsett M et al.)
- Frédérique PENAULT-LLORCA (Clermont-Ferrand)
- 12/01/2012
